Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65–79-year-olds and 13% (95% CI: −15 to 30) among those ≥ 80 years. As the A(H3N2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Rondy, Marc, Gherasim, Alin, Casado, Itziar, Launay, Odile, Rizzo, Caterina, Pitigoi, Daniela, Mickiene, Aukse, Marbus, Sierk D, Machado, Ausenda, Syrjänen, Ritva K, Pem-Novose, Iva, Horváth, Judith Krisztina, Larrauri, Amparo, Castilla, Jesús, Vanhems, Philippe, Alfonsi, Valeria, Ivanciuc, Alina E, Kuliese, Monika, van Gageldonk-Lafeber, Rianne, Gomez, Veronica, Ikonen, Niina, Lovric, Zvjezdana, Ferenczi, Annamária, Moren, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2017
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710120/
https://www.ncbi.nlm.nih.gov/pubmed/29043961
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.41.17-00645
Descripción
Sumario:In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65–79-year-olds and 13% (95% CI: −15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.

Ejemplares similares